Registered title, quoted from ClinicalTrials.gov
A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery
An open trial on lung cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 47 hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 47
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
- Study siteAffiliated Cancer Hospital of Guangzhou Medical University广州医科大学附属肿瘤医院GuangzhouHospital page
- Study siteAffiliated Hospital of Xuzhou Medical University徐州医科大学附属医院XuzhouHospital page
- Study siteAnhui Provincial Cancer Hospital安徽省肿瘤医院HefeiHospital page
- Study siteBeijing Chest Hospital首都医科大学附属北京胸科医院BeijingHospital page
- Study siteCentral Hospital Affiliated to Shandong First Medical University山东第一医科大学附属中心医院(济南市中心医院)JinanHospital page
- Study siteChina-Japan Friendship Hospital中日友好医院BeijingHospital page
- Study siteFirst Affiliated Hospital of Guangzhou Medical University广州医科大学附属第一医院GuangzhouHospital page
- Study siteFirst Affiliated Hospital of Xi'an Jiaotong University西安交通大学第一附属医院Xi'anHospital page
- Study siteFirst Affiliated Hospital of Zhengzhou University郑州大学第一附属医院ZhengzhouHospital page
- Study siteFirst Affiliated Hospital, Zhejiang University浙江大学医学院附属第一医院HangzhouHospital page
- Study siteFirst Hospital of China Medical University中国医科大学附属第一医院ShenyangHospital page
- Study siteFirst Hospital of Jilin University吉林大学第一医院ChangchunHospital page
- Study siteFudan University Shanghai Cancer Center复旦大学附属肿瘤医院ShanghaiHospital page
- Study siteFujian Cancer Hospital福建省肿瘤医院FuzhouHospital page
- Study siteFujian Medical University Union Hospital福建医科大学附属协和医院FuzhouHospital page
- Study siteGuangxi Medical University Cancer Hospital广西医科大学附属肿瘤医院NanningHospital page
- Study siteHarbin Medical University Cancer Hospital哈尔滨医科大学附属肿瘤医院HarbinHospital page
- Study siteHenan Cancer Hospital河南省肿瘤医院ZhengzhouHospital page
- Study siteHubei Cancer Hospital湖北省肿瘤医院WuhanHospital page
- Study siteHunan Cancer Hospital湖南省肿瘤医院ChangshaHospital page
- Study siteJiangsu Province Hospital江苏省人民医院(南医大一附院)NanjingHospital page
- Study siteLiaoning Cancer Hospital & Institute辽宁省肿瘤医院ShenyangHospital page
- Study siteNanjing Chest HospitalNanjingHospital page
- Study siteNational Cancer Center / Cancer Hospital, CAMS中国医学科学院肿瘤医院BeijingHospital page
- Study sitePeking Union Medical College Hospital北京协和医院BeijingHospital page
- Study sitePeking University Cancer Hospital北京大学肿瘤医院BeijingHospital page
- Study siteSecond Affiliated Hospital, Zhejiang University浙江大学医学院附属第二医院HangzhouHospital page
- Study siteShandong Cancer Hospital and Institute山东省肿瘤医院JinanHospital page
- Study siteShanghai Chest Hospital上海市胸科医院ShanghaiHospital page
- Study siteShanghai East Hospital, Tongji University同济大学附属东方医院ShanghaiHospital page
- Study siteShanghai Pulmonary Hospital上海市肺科医院ShanghaiHospital page
- Study siteShanxi Cancer Hospital山西省肿瘤医院TaiyuanHospital page
- Study siteSichuan Cancer Hospital四川省肿瘤医院ChengduHospital page
- Study siteSun Yat-sen Memorial Hospital中山大学孙逸仙纪念医院GuangzhouHospital page
- Study siteSun Yat-sen University Cancer Center中山大学肿瘤防治中心GuangzhouHospital page
- Study siteTaizhou Hospital, Wenzhou Medical University温州医科大学附属台州医院TaizhouHospital page
- Study siteThird Xiangya Hospital中南大学湘雅三医院ChangshaHospital page
- Study siteTianjin Chest Hospital天津市胸科医院TianjinHospital page
- Study siteTianjin Medical University Cancer Institute & Hospital天津医科大学肿瘤医院TianjinHospital page
- Study siteTianjin Medical University General Hospital天津医科大学总医院TianjinHospital page
- Study siteUnion Hospital华中科技大学同济医学院附属协和医院WuhanHospital page
- Study siteWest China Hospital四川大学华西医院ChengduHospital page
- Study siteXiangya Hospital中南大学湘雅医院ChangshaHospital page
- Study siteXuanwu Hospital首都医科大学宣武医院BeijingHospital page
- Study siteYunnan Cancer Hospital云南省肿瘤医院KunmingHospital page
- Study siteZhejiang Cancer Hospital浙江省肿瘤医院HangzhouHospital page
- Study siteZhongshan Hospital, Fudan University复旦大学附属中山医院ShanghaiHospital page
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07182682, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 6
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (6 points)Hide the checklist
18 years to Not stated; sex: all
Registered eligibility fields
Complete resection (R0) of the primary tumor and histologically confirmed diagnosis of NSCLC (participants with tumor histology indicative of neuroendocrine carcinoma, sarcomatoid carcinoma, or small cell lung cancer should be excluded).
Inclusion criterion 3
Participants must have NSCLC classified post-operatively as stage IB, II, or IIIA according to the AJCC TNM staging 9.0th edition.
Inclusion criterion 7
Participants must recover from prior lung surgery and systemic therapy (e.g., neoadjuvant therapy and/or adjuvant chemotherapy) without Grade 1 or higher AEs (except alopecia of any grade and ≤ Grade 2 platinum-associated neuropathy) at randomization.
Inclusion criterion 12
Participants who have not previously received adjuvant chemotherapy should be randomized as early as 4 weeks and within 10 weeks after the radical surgery.
Inclusion criterion 13
Participants who have previously received adjuvant chemotherapy can be randomized within 2 - 10 weeks of completion of adjuvant chemotherapy with a maximum interval of no more than 26 weeks from surgery to randomization. The adjuvant chemotherapy can start as early as 4 weeks after the radical surgery, in 21-day cycles, and up to 4 cycles.
Inclusion criterion 14
Male participants with female partners of child-bearing potential should use barrier contraceptives (e.g., by use of condoms), during their participation in this study and for 6 months following the last dose of the study drug. Male participants must refrain from donating sperm during their participation in the study and for 6 months following the last dose of the study drug. If male participants wish to father children, they should be advised to arrange for freezing of sperm samples prior to the start of study drug.
Inclusion criterion 16
Female participants of child-bearing potential should use reliable contraceptives from the time of screening until 2 months after discontinuation of study drug. Female participants should not be breast feeding and must have a negative pregnancy test (serum or urine β-human chorionic gonadotropin) prior to start dosing or must fulfil one of the following criteria at screening:
Inclusion criterion 17
Participants who have received any EGFR TKIs as (neo)adjuvant therapy for NSCLC or have known pathological complete response from previous neoadjuvant therapy.
Exclusion criterion 4
Prior history of atrial fibrillation within 6 months of the first dose of study drug, except for those related to drug treatment and recovered.
Exclusion criterion 12
Participants with a history of any malignancy, except for adequately treated non-melanoma skin cancer, carcinoma in situ or other solid tumors with >5 years since completion of anti-cancer therapy and no evidence of disease recurrence at randomization
Exclusion criterion 13
ECOG performance status is 0 or 1.
Inclusion criterion 11
Have documented EGFR exon20ins (Cohort 1) or EGFR PACC mutations (Cohort 2) from a local Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory (or equivalent).
Inclusion criterion 8
Common EGFR PACC mutations include, but not limited to, L718Q, G719X, S768I, L747P/S, V769L, E709_T710delinsD, L792H, and T854I.
Inclusion criterion 9
Concurrent EGFR sensitizing mutations (L858R and/or exon 19 deletion) or other driver gene variations with available standard therapies (e.g., ALK positive).
Exclusion criterion 1
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: scans and measurable lesions; other conditions the trial excludes; pregnancy, breastfeeding and contraception.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07182682, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Provide a signed and dated informed consent form (ICF) prior to any study specific procedures, sampling, and analyses.
- Aged at least 18 years old at the time of ICF signature.
- Complete resection (R0) of the primary tumor and histologically confirmed diagnosis of NSCLC (participants with tumor histology indicative of neuroendocrine carcinoma, sarcomatoid carcinoma, or small cell lung cancer should be excluded).
- Complete surgical resection of the primary NSCLC is mandatory. All gross lesions must be completely resected to achieve microscopically negative margins. Hilar and mediastinal lymph node dissection should be performed per clinical guidelines.
- Acceptable surgery type: lobectomy, sleeve lobectomy, bilobectomy, or pneumonectomy.
- Acceptable surgery approach: thoracotomy or thoracoscopic surgery.
- Participants must have NSCLC classified post-operatively as stage IB, II, or IIIA according to the AJCC TNM staging 9.0th edition.
- Have documented EGFR exon20ins (Cohort 1) or EGFR PACC mutations (Cohort 2) from a local Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory (or equivalent).
- Common EGFR PACC mutations include, but not limited to, L718Q, G719X, S768I, L747P/S, V769L, E709_T710delinsD, L792H, and T854I.
- Participants must provide sufficient tumor tissue samples for confirmation of EGFR mutations by the sponsor designated central laboratory.
- ECOG performance status is 0 or 1.
- Participants must recover from prior lung surgery and systemic therapy (e.g., neoadjuvant therapy and/or adjuvant chemotherapy) without Grade 1 or higher AEs (except alopecia of any grade and ≤ Grade 2 platinum-associated neuropathy) at randomization.
- Participants who have not previously received adjuvant chemotherapy should be randomized as early as 4 weeks and within 10 weeks after the radical surgery.
- Participants who have previously received adjuvant chemotherapy can be randomized within 2 - 10 weeks of completion of adjuvant chemotherapy with a maximum interval of no more than 26 weeks from surgery to randomization. The adjuvant chemotherapy can start as early as 4 weeks after the radical surgery, in 21-day cycles, and up to 4 cycles.
- Adequate bone marrow reservation or organ functions within 7 days prior to randomization.
- Male participants with female partners of child-bearing potential should use barrier contraceptives (e.g., by use of condoms), during their participation in this study and for 6 months following the last dose of the study drug. Male participants must refrain from donating sperm during their participation in the study and for 6 months following the last dose of the study drug. If male participants wish to father children, they should be advised to arrange for freezing of sperm samples prior to the start of study drug.
- Female participants of child-bearing potential should use reliable contraceptives from the time of screening until 2 months after discontinuation of study drug. Female participants should not be breast feeding and must have a negative pregnancy test (serum or urine β-human chorionic gonadotropin) prior to start dosing or must fulfil one of the following criteria at screening:
- Post-menopausal defined as aged at least 50 years old and amenorrhea for at least 12 months following cessation of all exogenous hormonal treatment.
- Women under 50 years old would be considered postmenopausal if they have been amenorrheic for ≥ 12 months following cessation of exogenous hormonal treatments and with luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels in the post-menopausal range.
- Documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy or bilateral salpingectomy but not tubal ligation.
Exclusion Criteria:
- Concurrent EGFR sensitizing mutations (L858R and/or exon 19 deletion) or other driver gene variations with available standard therapies (e.g., ALK positive).
- Participants who have had only segmentectomies or wedge resections.
- Participants who have received any preoperative or postoperative radiotherapy for NSCLC, or who plan to have radiotherapy during the study.
- Participants who have received any EGFR TKIs as (neo)adjuvant therapy for NSCLC or have known pathological complete response from previous neoadjuvant therapy.
- Participants who are receiving (or unable to stop) medications or herbs known to be strong CYP3A inducers within 2 weeks prior to randomization.
- Previous history of interstitial lung disease (ILD), drug-induced ILD, or radiation pneumonitis requiring steroid therapy, any evidence of clinically active ILD, or immunotherapy induced pneumonitis.
- Any serious or uncontrolled systemic disease requiring treatment, including uncontrolled hypertension, diabetes, chronic heart failure and active bleeding disorders (such as hemophilia, von Willebrand disease), etc., which in the opinion of the investigator is not suitable for participation in the trial or will affect compliance with the protocol; or active infection, including hepatitis B, hepatitis C and human immunodeficiency virus (HIV).
- Any of the following cardiac criteria:
- Mean resting corrected QT interval (QTc) > 470 msec on 3 ECGs at screening
- Any clinically significant abnormalities in rhythm, conduction or morphology of resting ECG, e.g., complete left bundle branch block, third degree heart block, and second-degree heart block, PR interval > 250 msec.
- Any factors that increase the risk of QTc prolongation, such as heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years old in first degree relatives or any concomitant medication known to prolong the QT interval.
- Prior history of atrial fibrillation within 6 months of the first dose of study drug, except for those related to drug treatment and recovered.
- Participants with a history of any malignancy, except for adequately treated non-melanoma skin cancer, carcinoma in situ or other solid tumors with >5 years since completion of anti-cancer therapy and no evidence of disease recurrence at randomization
- Refractory nausea and vomiting, chronic gastrointestinal disease, inability to swallow the formulated product, or previous major bowel resection that may preclude adequate absorption of sunvozertinib.
- Hypersensitivity to sunvozertinib, excipients of sunvozertinib, or drugs of similar chemical structure or same class.
- Involvement in the design, planning or conduct of this study (applicable to Dizal staff or study site staff).
- Judgment by the investigator that the participant is unlikely to comply with study procedures, restrictions or requirements.
Quoted from ClinicalTrials.gov, NCT07182682, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07182682, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.